<DOC>
	<DOCNO>NCT00290641</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , cyclophosphamide fludarabine , radiation therapy donor umbilical cord blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This clinical trial study well give chemotherapy together total-body irradiation follow donor umbilical cord blood transplant , cyclosporine , mycophenolate mofetil work treat patient hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy Total-Body Irradiation Followed Donor Umbilical Cord Blood Transplant , Cyclosporine , Mycophenolate Mofetil Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine engraftment potential unrelated allogeneic umbilical cord blood ( UCB ) use nonmyeloablative conditioning comprise fludarabine , cyclophosphamide , total-body irradiation follow post-transplant immunosuppression comprise cyclosporine mycophenolate mofetil patient hematologic malignancy . Secondary - Determine rate neutrophil platelet recovery completeness donor cell engraftment patient treat regimen . - Determine incidence severity acute chronic graft-versus-host disease ( GVHD ) patient treat regimen . - Determine incidence malignant relapse patient treat regimen . - Determine 1- 2-year survival event-free survival patient treat regimen . - Determine phenotype function immune cell recover UCB transplantation patient treat regimen . - Determine toxicity regimen patient . OUTLINE : Patients stratify accord HLA disparity ( 0-1 v 2 ) number graft unit ( 1 vs 2 ) . - Nonmyeloablative conditioning : Patients receive nonmyeloablative conditioning comprise fludarabine IV 1 hour day -8 -6 cyclophosphamide IV 2 hour day -7 -6 . Patients undergo total-body irradiation twice daily day -4 -1 . - Unrelated allogeneic umbilical cord blood transplantation ( UCBT ) : Patients undergo 1 2 unrelated allogeneic UCBTs day 0 . - Immunosuppression : Patients receive cyclosporine orally IV 2 hour 2-3 time daily begin day -3 continue day 100 , follow taper absence graft-vs-host disease ( GVHD ) . Patients also receive mycophenolate mofetil orally IV twice daily day -3 30 , continue beyond day 30 donor engraftment . Patients also receive filgrastim ( G-CSF ) IV subcutaneously begin day 1 continue blood count recover . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hematologic malignancy 1 follow type : Acute myeloid leukemia ( AML ) , meet follow criterion : In complete remission ( CR ) morphology ( &lt; 5 % blast bone marrow ) , define 1 following : In first CR ( CR1 ) meet ≥ 1 follow highrisk criterion : Highrisk cytogenetics ( e.g. , associate myelodysplastic syndrome [ MDS ] complex karotype ) Preceding MDS More 2 course therapy require obtain CR In second great CR No morphologic relapse Cytogenetic relapse persistent disease allow Acute lymphocytic leukemia ( ALL ) , meet follow criterion : In CR , define 1 following : In CR1 meet ≥ 1 follow highrisk criterion : Unfavorable highrisk cytogenetics [ ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) MLL rearrangements ] More 1 course therapy require obtain CR In second great CR No morphologic relapse persistent disease Chronic myelogenous leukemia ( CML ) , exclude refractory blast crisis Advanced myelofibrosis Advanced myelodysplasia ( blast &lt; 10 % [ otherwise need AML induction pretransplant ] ) , meet ≥ 1 follow criterion : Refractory anemia excess blast ( RAEB ) RAEB transformation Refractory anemia severe pancytopenia Highrisk cytogenetics NonHodgkin 's lymphoma ( NHL ) , meet follow criterion : One follow histologic subtypes : Mantle cell NHL Disease progression initial therapy ( e.g. , CHOP ) Beyond CR1 beyond first partial remission ( PR ) Intermediategrade NHL second great CR PR Highgrade NHL Stage III IV disease AND receive initial therapy Stage I II disease diagnosis subsequently progress prior response duration &lt; 1 year No chemotherapyrefractory NHL ( i.e. , &lt; progressive disease &gt; 2 salvage regimen ) Donor available , meet follow criterion : No exist HLAidentical relate donor available 46/6 HLAA , B , DRB1 , match unrelated donor molecular techniques A B antigen level resolution DR allele resolution Umbilical cord blood ( UCB ) graft may consist one two UCB unit NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Karnofsky score 80100 % ( adult ) OR Lansky score 50100 % ( child ) Creatinine ≤ 2.0 mg/dL ( adult ) OR creatinine clearance &gt; 40 mL/min ( child ) Adults creatinine &gt; 1.2 mg/dL history renal dysfunction must creatinine clearance &gt; 40 mL/min Bilirubin ≤ 2 time normal AST ALT ≤ 2 time normal Alkaline phosphatase ≤ 2 time normal Pulmonary function &gt; 50 % normal LVEF ≥ 45 % No active infection , include Aspergillus mold , within past 30 day No history HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior myeloablative transplant within past 6 month ≤ 18 year old No prior myeloablative allotransplant autologous transplant &gt; 18 year old No prior extensive therapy ( e.g. , &gt; 12 month alkylating therapy &gt; 6 month alkylating therapy extensive radiation )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>